Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	289.68	172.35	23.68	-	-	139.71
Revenue Growth	160.26%	627.84%	-	-	-	9109.56%
Cost of Revenue	295.55	265.75	242.47	163.03	118.5	-
Gross Profit	-5.87	-93.4	-218.79	-163.03	-118.5	139.71
Selling, General & Admin	172.77	179.68	120.88	66.92	33.26	25.24
Research & Development	-	-	-	-	-	88.25
Operating Expenses	172.77	179.68	120.88	66.92	33.26	113.49
Operating Income	-178.64	-273.08	-339.67	-229.95	-151.76	26.22
Interest Expense	-47.09	-33.79	-4.93	-0.21	-3.14	-1.9
Interest & Investment Income	17.23	22.73	26.09	21.16	5.87	0.4
Other Non Operating Income (Expenses)	-0.98	-1.28	-0.25	-0.36	-0.32	0.2
Pretax Income	-209.48	-285.42	-318.76	-209.36	-149.34	24.93
Net Income	-209.48	-285.42	-318.76	-209.36	-149.34	24.93
Net Income to Common	-209.48	-285.42	-318.76	-209.36	-149.34	24.93
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	88	87	86	70	61	52
Shares Outstanding (Diluted)	88	87	86	70	61	54
Shares Change	2.25%	1.17%	21.67%	15.82%	13.31%	29.81%
EPS (Basic)	-2.37	-3.29	-3.72	-2.98	-2.46	0.48
EPS (Diluted)	-2.37	-3.29	-3.72	-2.98	-2.46	0.46
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-177.46	-323.17	-274.9	-160.6	-133.68	29
Free Cash Flow Per Share	-2.00	-3.73	-3.21	-2.28	-2.20	0.54
Gross Margin	-2.03%	-54.19%	-	-	-	100.00%
Operating Margin	-61.67%	-158.45%	-1434.43%	-	-	18.77%
Profit Margin	-72.32%	-165.60%	-1346.11%	-	-	17.84%
Free Cash Flow Margin	-61.26%	-187.50%	-1160.91%	-	-	20.76%
EBITDA	-178.62	-273.08	-339.66	-229.94	-151.72	26.26
EBITDA Margin	-61.66%	-158.44%	-	-	-	18.80%
D&A For EBITDA	0.02	0.01	0.01	0.01	0.03	0.04
EBIT	-178.64	-273.08	-339.67	-229.95	-151.76	26.22
EBIT Margin	-61.67%	-158.45%	-	-	-	18.77%
Revenue as Reported	289.68	172.35	23.68	-	-	139.71
Advertising Expenses	-	14.4	7.3	6.1	1.5	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error